OneCell Diagnostics bags $16M to help limit cancer reoccurrence using AI

Quick Summary:

The fresh capital will help OneCell expand into the U.S.and scale its business in India, Uttarwar said.

The startup provides its biopsy testing for pan-cancer analysis for all solid tumors, including breast, lung, and colon cancers.

The startup combines the circulating tumor cell-DNA with its RNA and cell surface protein testing.

---

More Pictures

---

Read Quick SummarySave Time

or

Article Details

Author / Journalist: Jagmeet Singh

Category: Technology

Markets: United StatesGeorgiaIndia

Topics: OneCell Diagnostics Celesta Capital Exclusive Startups

Source Website Secure: Yes (HTTPS)

News Sentiment: Positive

Fact Checked: Legitimate

Article Type: News Report

Published On: 2024-11-21 @ 04:00:00 (13 hours ago)

News Timezone: GMT -5:00

News Source URL: techcrunch.com

Language: English

Article Length: 864 words

Reading Time: 5 minutes read

Sentences: 39 lines

Sentence Length: 23 words per sentence (average)

Platforms: Desktop Web, Mobile Web, iOS App, Android App

Copyright Owner: © TechCrunch

News ID: 23728059

View Article Analysis

About TechCrunch

Main Topics: Technology

Official Website: techcrunch.com

Update Frequency: 24 posts per day

Year Established: 2005

Headquarters: United States

News Last Updated: 9 hours ago

Coverage Areas: United States

Ownership: Independent Company

Publication Timezone: GMT -5:00

Content Availability: Worldwide

News Language: English

RSS Feed: Available (XML)

API Access: Available (JSON, REST)

Website Security: Secure (HTTPS)

Publisher ID: #20

Publisher Details

Frequently Asked Questions